Profil
Douglas Maffei is currently the Vice President-Investor Relations at Seagen Inc. He previously worked as a Senior Director-Investor Relations at Gilead Sciences, Inc.
Postes actifs de Douglas Maffei
| Sociétés | Poste | Début |
|---|---|---|
| SEAGEN INC. | Investor Relations Contact | - |
Anciens postes connus de Douglas Maffei
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
